Filtered By:
Condition: Thrombosis
Procedure: Coronary Angioplasty
This page shows you your search results in order of relevance. This is page number 8.
Order by Relevance | Date
Total 869 results found since Jan 2013.
Predictive models for adverse clinical outcomes in Chinese patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting
CONCLUSION: Chinese patients with AF and coronary stenting had high mortality and incidence of MACCE. We compiled separate predictive models for all-cause death, IS/STE, MACCE, and major bleeding.PMID:34353224 | DOI:10.1080/00015385.2021.1950367
Source: Acta Cardiologica - August 6, 2021 Category: Cardiology Authors: Jian-Yong Zheng Yi Cao Dong-Tao Li Yi-Gang Qiu Li Zhao Zheng-Ming Xu Yi-Xiong Huang Zhi-Bo Hong Tian-Chang Li Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yu Chen Source Type: research
Very Short Versus Longer Dual Antiplatelet Treatment After Coronary Interventions: A Systematic Review and Meta-analysis
ConclusionsVSDAPT significantly decreased the odds of NACEs and major bleeding by 17% and 29%, respectively, without increasing ischemic events. Thus, VSDAPT could be well tolerated and feasible after PCI with DES.Clinical Trials RegistrationOpen Science Framework (10.17605/OSF.IO/4H2JB)Graphical AbstractVery short-term DAPT significantly reduces NACE and major bleedings, without affecting mortality and ischemic events (MACE, MI, stroke, stent thrombosis and revascularization).CI confidence intervals,DAPT dual antiplatelet therapy,DES drug-eluting stents,MACE major adverse cardiovascular events,MI myocardial infarction,NAC...
Source: American Journal of Cardiovascular Drugs - December 20, 2022 Category: Cardiology Source Type: research
Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention
ConclusionsThe utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Source: European Journal of Clinical Pharmacology - February 24, 2023 Category: Drugs & Pharmacology Source Type: research
Short Versus Long-Term Dual Antiplatelet Therapy in Patients at High Bleeding Risk Undergoing PCI in Contemporary Practice: A Systemic Review and Meta-analysis
ConclusionShort-term DAPT after PCI in HBR patients was associated a reduction in major bleeding events and similar ischemic outcomes. However, a higher risk of ischemic stroke and MI at 1 year of follow-up was seen in some subsets.
Source: Cardiology and Therapy - June 1, 2023 Category: Cardiology Source Type: research
Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: a meta-analysis.
CONCLUSIONS: Triple therapy is more efficacious in reducing the occurrence of ischemic stroke in PCI-s patients with an indication of chronic oral anticoagulation (OAC), compared with DAPT. However, it significantly increased major and minor risk of bleeding. It is imperative that further prospective randomized controlled trials are required to defne the best therapeutic strategy for patients with an indication of chronic OAC undergoing PCI-s.
PMID: 23823830 [PubMed - in process]
Source: Chinese Medical Journal - July 1, 2013 Category: Journals (General) Authors: Saheb KJ, Deng BQ, Hu QS, Xie SL, Geng DF, Nie RQ Tags: Chin Med J (Engl) Source Type: research
Unanswered Questions in Patients With Concurrent Atrial Fibrillation and Acute Coronary Syndrome
In conclusion, until the results of additional ongoing or planned randomized trials are known, clinicians must continue to rely on expert opinion and their own clinical judgment when treating these patients.
Source: The American Journal of Cardiology - December 16, 2013 Category: Cardiology Authors: Daniel S. Ice, Timothy A. Shapiro, Eric M. Gnall, Peter R. Kowey Tags: Review Source Type: research
Bivalirudin in percutaneous coronary intervention: The EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry
Conclusion: In this prospective registry of consecutive patients intended for PCI, use of BIV was associated with low rates of ischemic complications and excellent safety.
Source: International Journal of Cardiology - March 28, 2014 Category: Cardiology Authors: Martial Hamon, Christopher A. Nienaber, Stefano Galli, Kurt Huber, Janusz Lipiecki, Jonathan M. Hill, Nicolas Amabile, Debra Bernstein, Efthymios Deliargyris, Antoine Lafont, Philippe Gabriel Steg Tags: Original Articles Source Type: research
Angiographic success and procedural complications in patients undergoing retrograde percutaneous coronary chronic total occlusion interventions: A weighted meta-analysis of 3482 patients from 26 studies
Conclusions: Retrograde CTO PCI is associated with high procedural success rate and acceptable risk for procedural complications.
Source: International Journal of Cardiology - April 25, 2014 Category: Cardiology Authors: Abdallah El Sabbagh, Vishal G. Patel, Omar M. Jeroudi, Tesfaldet T. Michael, Mohammed E. Alomar, Owen Mogabgab, Eric Fuh, Michele Roesle, Bavana V. Rangan, Shuaib Abdullah, Jeffrey L. Hastings, Jerrold Grodin, Dharam J. Kumbhani, Dimitrios Alexopoulos, Pa Tags: Reviews Source Type: research
Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction
Conclusion
In this randomized trial of STEMI patients, we were unable to demonstrate significant differences in net clinical outcome between prasugrel plus bivalirudin and clopidogrel plus heparin. Neither the composite of ischaemic complications nor bleeding were favourably affected by prasugrel plus bivalirudin compared with a regimen of clopidogrel plus unfractionated heparin. However, the results must be interpreted in view of the premature termination of the trial.
Clinical trial registration information
Unique identifier NCT00976092 (www.clinicaltrials.gov).
Source: European Heart Journal - September 7, 2014 Category: Cardiology Authors: Schulz, S., Richardt, G., Laugwitz, K.-L., Morath, T., Neudecker, J., Hoppmann, P., Mehran, R., Gershlick, A. H., Tolg, R., Anette Fiedler, K., Abdel-Wahab, M., Kufner, S., Schneider, S., Schunkert, H., Ibrahim, T., Mehilli, J., Kastrati, A., and for the Tags: FASTTRACK CLINICAL RESEARCH Source Type: research
Triple Therapy for Atrial Fibrillation and Percutaneous Coronary Intervention A Contemporary Review
Chronic oral anticoagulant therapy is recommended (class I) in patients with mechanical heart valves and in patients with atrial fibrillation with a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack or thromboembolism, Vascular disease, Age 65 to 74 years, Sex category) score ≥1. When these patients undergo percutaneous coronary intervention with stenting, treatment with aspirin and a P2Y12 receptor inhibitor also becomes indicated. Before 2014, guidelines recommended the use of triple therapy (vitamin K antagonists, aspirin, and clopidog...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - September 15, 2014 Category: Cardiology Source Type: research
Five-year outcomes of staged percutaneous coronary intervention in the SYNTAX study.
CONCLUSIONS: There is a higher incidence of MACCE in patients undergoing staged compared to single-session PCI for 3-vessel and/or left main disease over the first five years of follow-up. However, these patients had more comorbidities and more diffuse disease.
PMID: 25912390 [PubMed - in process]
Source: EuroIntervention - May 1, 2015 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome.
CONCLUSION: DAPT for >6months do not seem to be associated with improved clinical outcomes in patients with ACS undergoing percutaneous coronary intervention (PCI) with ZES.
PMID: 26153337 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - July 4, 2015 Category: Internal Medicine Authors: Song PS, Hahn JY, Kim DI, Song YB, Choi SH, Choi JH, Ryu DR, Hur SH, Jeong JO, Park HS, Kim HS, Gwon HC Tags: Eur J Intern Med Source Type: research
